Analysts Expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Will Announce Quarterly Sales of $1.56 Million
Wall Street brokerages forecast that Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) will announce sales of $1.56 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.30 million to $1.88 million. Tetraphase Pharmaceuticals posted sales of $1.24 million in the same quarter last year, which suggests a positive year over year growth rate of 25.8%. The business is expected to report its next earnings results on Thursday, August 3rd.
On average, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $1.56 million for the current financial year, with estimates ranging from $4.99 million to $7.11 million. For the next financial year, analysts expect that the firm will post sales of $5.13 million per share, with estimates ranging from $3.00 million to $7.51 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative return on equity of 60.55% and a negative net margin of 1,932.24%. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.46 million. During the same period last year, the company posted ($0.46) earnings per share. The business’s quarterly revenue was down 24.5% on a year-over-year basis.
Several equities analysts have issued reports on TTPH shares. BMO Capital Markets reissued a “buy” rating and issued a $12.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 5th. HC Wainwright started coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $8.45.
Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 7.80 on Friday. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93. The company’s 50-day moving average is $7.48 and its 200-day moving average is $6.43. The stock’s market capitalization is $296.06 million.
Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after buying an additional 230,420 shares in the last quarter. Tekla Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 422.2% in the first quarter. Tekla Capital Management LLC now owns 1,004,322 shares of the biopharmaceutical company’s stock valued at $9,230,000 after buying an additional 812,000 shares in the last quarter. State Street Corp raised its stake in Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock valued at $2,864,000 after buying an additional 11,391 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Tetraphase Pharmaceuticals by 180.4% in the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after buying an additional 408,078 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in Tetraphase Pharmaceuticals by 108.2% in the first quarter. Acadian Asset Management LLC now owns 379,049 shares of the biopharmaceutical company’s stock valued at $3,482,000 after buying an additional 197,022 shares in the last quarter. Institutional investors and hedge funds own 47.77% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.